drugset / Trial / NCT02586987
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
Timeline
- Start
- 2015-12-28
- Primary completion
- 2018-07-25
- Completion
- 2019-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Selumetinib | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |